The Bloom #142 Free Edition PsyPal, not PayPal

​

The FDA has received Lykos' (MAPS PBC) application and has given it priority review. This means a decision can be expected as soon as August this year.

In the meantime, several research articles investigated the effects of MDMA in two very different settings. The first looked at the impact of recreational use of MDMA, showing that intention predicted long-term positive outcomes (not setting). The second study compared methylone against MDMA in (rat) brain cells, showing the former to have less off-target effects.

Many studies pose different theories as to why psychedelics work. Two broad theories (at the psychological level) pit mysticism against insights. An analysis of online trip reports now argues that psychological insight predicted positive outcomes (not mystical beliefs).

Floris - Founder of Blossom

ps Learn about how GMP psychedelics are made by experts Dr. Preston A. Chase & Karina Lahnakoski during a live webinar today at 2 pm PST. Register for a front-row and behind-the-scenes look at the current and future state of GMP psychedelic manufacturing.​

Latest Psychedelic Research

1 What Predicts Beneficial Outcomes in Psychedelic Use?​

This analysis (n=240) of online trip reports examines the mechanisms behind the therapeutic potential of psychedelics, comparing metaphysical belief theory and predictive self-binding theory. Path analysis and structural equation modelling reveal that psychological insight, rather than metaphysical beliefs, uniquely predicts beneficial outcomes. Additionally, the positive effects of ego dissolution and therapeutic intent on beneficial outcomes are fully mediated by psychological insight, thereby supporting the predictive self-binding model over the metaphysical belief theory.

Related: Who Are You After Psychedelics?​

2 Subjective long-term emotional and social effects of recreational MDMA use: the role of setting and intentions​

This survey study (n=766) explores the consumption habits and perceived long-term social-emotional effects of MDMA use among individuals aged 18–61, primarily from Western countries. Utilizing a K-medoids clustering algorithm, researchers identified three consumption setting types—party settings with friends (n=388), private home settings (n=132), and mixed settings (n=246)—and three intention types—euphoria and energy (n=302), self-insight (n=219), and mixed intentions (n=245). The study found that individuals in the self-insight and mixed intentions clusters reported more long-term socio-emotional benefits compared to those seeking solely euphoria and energy, with no significant differences observed between the setting clusters.

3 Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA​

This preclinical study (in cells) investigated methylone's potential for treating PTSD, comparing it with MDMA. Methylone showed rapid antidepressant and anxiolytic effects in preclinical models, affecting gene expression related to neuroplasticity in brain areas associated with PTSD and MDD. Unlike MDMA, methylone demonstrated no off-target effects at various receptors, indicating potential higher specificity, and suggesting its potential use in treating PTSD and other neuropsychiatric disorders.

2 Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants​

This Phase I study (n=44) investigates the safety, tolerability, pharmacokinetics, and -dynamic profile of escalating doses of SPL026 (DMT fumarate; 9-21.5mg) in psychedelic-naïve healthy participants. The RCT concludes that SPL026 was well-tolerated, showing an acceptable safety profile, with potential correlations between plasma concentration and psychometric measures.

3 MDMA enhances positive affective responses to social feedback​

This double-blind, placebo-controlled crossover trial (n=36) investigates the effects of two doses of MDMA (52.5-105mg/70kg) compared to both placebo and methamphetamine (20 mg) on responses to personalized social feedback in healthy adults. The study concludes that the higher dose of MDMA increases positive affective responses to social feedback, suggesting a potential mechanism by which MDMA may enhance social connection.

More new research

• ​Effects of DMT on mental health outcomes in healthy volunteers​
• ​Psychedelics and sexual functioning: a mixed-methods study​
• ​Effects of Ayahuasca on Gratitude and Relationships with Nature: A Prospective, Naturalistic Study​
• ​Modulation of long-term potentiation following microdoses of LSD captured by thalamo-cortical modelling in a randomised, controlled trial​
• ​Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study​
• ​Effects of hallucinogenic drugs on the human heart​

New on Blossom

1 Psychedelic Research Recap January 2024​

January saw new psychedelic trials on ibogaine for TBI, DMT, and psilocybin for CCHs, alongside re-analyses on psychedelic brain impacts, therapy dynamics in MDMA treatment, and LSD visuals. Studies also probed SSRI-psychedelic interactions, expectancy roles, and heart effects from microdosing.

2 Psychedelic Research Links 2024​

All the other papers that have come out this year that don't have a separate entry in the database.

Spotlight

1 Know Your Psychedelic Drug Candidate (Event)

Join Optimi Health's webinar on Feb 13, 2024, at 2 PM PST to delve into GMP psychedelic drug standards with experts Dr. Preston A. Chase & Karina Lahnakoski. Learn about safe, quality psychedelic therapy production and its future.

Are you a clinician, researcher, therapist, pharmacist, or regulator?

Are you currently researching the safety and efficacy of psychedelics in a clinical trial?

Are you currently treating patients through a regulated compassionate access program?

Are you wanting to learn more about the cultivation and formulation of true end-to-end GMP psychedelics?

If you answered yes to any of these questions, then please join Optimi Health Chief Science Officer, Dr. Preston A. Chase, and Director of Quality Commercial Strategies, Karina Lahnakoski, as they provide a rare glimpse into the commercial manufacturing and formulation of Optimi's GMP psychedelic drug candidates.

2 Hystelica's Pioneering Psychedelic Research on Menstrual and Menopause Symptoms (Survey)

Hystelica has launched one of the first women-focused research for the effects of psychedelics on symptoms of the menstrual cycle or menopause.

They hope this research will form a base from which we can begin to piece together hypotheses for future research and a greater understanding of how psychedelics may be impactful to women, particularly around the effects of large psychedelic 'trip' on menstrual and menopause symptoms (of which we currently really don't know very much at all!).

Hystelica aims to get as many eligible women as possible to complete this research.

So, support their work by answering their survey. Hystelica is looking for women over the age of 18 who have experience using macro doses of psychedelics to complete the survey.

​

Molenvaart 76, Anna Paulowna, NH 1761AL
​Unsubscribe · Preferences​